Breast Cancer Clinical Trials in Indianapolis, Indiana

9 studies are recruiting for breast cancer in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Community Health Network, Inc, Indianapolis, Indiana

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

3. HER2 Vaccine for Locally Advanced Breast Cancer

   The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Pravin T.P Kaumaya

   See if you can join NCT06949410 on ClinicalTrials.gov

4. ATEMPT 2.0: Adjuvant T-DM1 vs TH

   This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Locations

   53 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04893109 on ClinicalTrials.gov

5. Exercise in Metastatic Breast Cancer: EMBody

   The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, supervised, progressive intensity aerobic and resistance train…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana

   Locations

   6 in total

   Run by

   Indiana University

   See if you can join NCT05468034 on ClinicalTrials.gov

6. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

   This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   7 in total

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT04841148 on ClinicalTrials.gov

7. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

   This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The st…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Indianapolis, Indiana

   Locations

   7 in total

   Run by

   Hummingbird Bioscience

   See if you can join NCT06956690 on ClinicalTrials.gov

8. NearWave Optical Molecular Monitoring

   The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT06744465 on ClinicalTrials.gov

9. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

   This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   37 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT05216432 on ClinicalTrials.gov